Literature DB >> 6607419

Serum ferritin in haemodialysis patients: role of blood transfusions and 'haemochromatosis alleles' HLA A3, B7 and B14.

E Gómez, F Ortega, R Peces, E Gago, R Marín, J Alvarez Grande.   

Abstract

In 48 patients on maintenance haemodialysis (HD), serum ferritin (SF) levels were measured and compared with 'haemochromatosis alleles', (HA), HLA A3, B7 and B14. A positive correlation was found between high SF levels and the presence of HA. When patients who had received 10 or fewer blood transfusions were studied, it was observed that this correlation did not exist, but it was evident, however, in patients who had received more than 10 blood transfusions. After 14 months in which blood transfusions were restricted, no significant difference in SF was observed between HA carriers and the rest. Our findings suggest that repeated blood transfusions can cause high SF in HD patients, especially in those with HLA A3, B7 or B14 antigens. Among our patients, restriction of blood transfusions seems sufficient to decrease high SF levels.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6607419     DOI: 10.1159/000183127

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  3 in total

1.  A study of 609 HLA haplotypes marking for the hemochromatosis gene: (1) mapping of the gene near the HLA-A locus and characters required to define a heterozygous population and (2) hypothesis concerning the underlying cause of hemochromatosis-HLA association.

Authors:  M Simon; L Le Mignon; R Fauchet; J Yaouanq; V David; G Edan; M Bourel
Journal:  Am J Hum Genet       Date:  1987-08       Impact factor: 11.025

2.  MRI of hepatic iron deposition in patients with renal transplant.

Authors:  F H Miller; M R Fisher; W Soper; R M Gore
Journal:  Gastrointest Radiol       Date:  1991

3.  Diagnosis and treatment of iron overload in paediatric patients on chronic haemodialysis.

Authors:  F J Eijgenraam; R A Donckerwolcke; P J van Dijken
Journal:  Pediatr Nephrol       Date:  1988-07       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.